A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery

被引:39
作者
Dansirikul, Chantaratsamon [1 ]
Lehr, Thorsten [1 ]
Liesenfeld, Karl-Heinz [1 ]
Haertter, Sebastian [1 ]
Staab, Alexander [1 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med, D-88397 Biberach, Germany
关键词
Dabigatran etexilate; NONMEM; pharmacometrics; population pharmacokinetics / pharmacodynamics; thrombin inhibitor; THROMBIN INHIBITOR DABIGATRAN; ORAL DIRECT THROMBIN; POPULATION PHARMACOKINETIC ANALYSIS; TOTAL HIP-REPLACEMENT; PHARMACODYNAMICS; WARFARIN; PERFORMANCE; METABOLISM; SAFETY;
D O I
10.1160/TH11-09-0656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Dabigatran etexilate is the orally bioavailable pro-drug of dabigatran, a direct thrombin inhibitor. Using data from eight clinical studies in healthy volunteers and patients with non-valvular atrial fibrillation (AF) or undergoing orthopaedic surgery (05), population pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to investigate whether the PK and PD of dabigatran differ across different populations. In both healthy volunteers (n=80) and patients (n=1,965), the PK of dabigatran was best described by a two-compartment disposition model with first-order absorption and elimination. Renal function was the only covariate shown to have a clinically relevant impact on dabigatran exposure. The patient PK model was successfully applied in predicting exposure observed in the RE-LY trial evaluating dabigatran treatment in patients with non-valvular AF. The relationship between dabigatran plasma concentrations and activated partial thromboplastin time in healthy volunteers and patients (n=762) was best described with a combination of a linear model and a maximum effect (E-max) model, consistent with previous reports. PK/PD relationships were robust across the various populations tested and were not affected by any of the covariates examined. In summary, the PK of dabigatran is sufficiently consistent to allow extrapolation of data generated in healthy volunteers to patients with AF or undergoing OS.
引用
收藏
页码:775 / 785
页数:11
相关论文
共 33 条
  • [11] Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
    Friedman, R. J.
    Dahl, O. E.
    Rosencher, N.
    Caprini, J. A.
    Kurth, A. A.
    Francis, C. W.
    Clemens, A.
    Hantel, S.
    Schnee, J. M.
    Eriksson, B. I.
    [J]. THROMBOSIS RESEARCH, 2010, 126 (03) : 175 - 182
  • [12] Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate
    Haertter, Sebastian
    Yamamura, Norio
    Stangier, Joachim
    Reilly, Paul A.
    Clemens, Andreas
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) : 260 - 269
  • [13] Jonsson EN, 1999, COMPUT METH PROG BIO, V58, P51, DOI 10.1016/S0169-2607(98)00067-4
  • [14] Pharmacokinetics and drug metabolism in the elderly
    Klotz, Ulrich
    [J]. DRUG METABOLISM REVIEWS, 2009, 41 (02) : 67 - 76
  • [15] Lehr T., 2011, J. Clin. Pharmacol
  • [16] Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
    Liesenfeld, K-H
    Lehr, T.
    Dansirikul, C.
    Reilly, P. A.
    Connolly, S. J.
    Ezekowitz, M. D.
    Yusuf, S.
    Wallentin, L.
    Haertter, S.
    Staab, A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (11) : 2168 - 2175
  • [17] Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients:: a population model analysis
    Liesenfeld, Karl-Heinz
    Schaefer, Hans G.
    Troconiz, Ioaki F.
    Tillmann, Christiane
    Eriksson, Bengt I.
    Stangier, Joachim
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (05) : 527 - 537
  • [18] A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models
    Parke, J
    Holford, NHG
    Charles, BG
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 1999, 59 (01) : 19 - 29
  • [19] Extensions to the Visual Predictive Check to facilitate model performance evaluation
    Post, Teun M.
    Freijer, Jan I.
    Ploeger, Bart A.
    Danhof, Meindert
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2008, 35 (02) : 185 - 202
  • [20] Rathgen K, 2005, BIOAVAILABILITY BIBR